BCR and diffuse large B-cell lymphoma: For the costimulatory domains, data recently published in a meta-analysis focused on patients with diffuse large B-cell lymphoma (DLBCL) treated with CD19 CAR T cells corroborated our findings, showing higher BCR and BOR rates of CD28 (57% BCR and 81% BOR) compared to 4-1BB (42% BCR and 70% BOR).